J&J strikes $2.2 billion buyout deal for eye disease biotech Ollin Biosciences Investing.com · News 13m ago
Creative Realities earnings missed by $0.25, revenue fell short of estimates Investing.com · News 15m ago
Our Bond approves conversion of Series B preferred stock to common shares Investing.com · News 19m ago
Kodiak Sciences at Jefferies Global Healthcare Conference: pipeline nears key readouts Investing.com · News 22m ago
Parabilis Medicines at Jefferies Global Healthcare Conference: pipeline gains Investing.com · News 23m ago